General Catalyst is a venture capital firm established in 2000, headquartered in Cambridge, Massachusetts, with additional offices in North America and Europe. The company specializes in early-stage and growth equity investments, focusing on technology-driven businesses. It invests across various sectors, including consumer internet, enterprise software, fintech, health assurance, and crypto. General Catalyst provides not only capital but also mentorship and resources to accelerate the growth of its portfolio companies. To date, it has managed eight venture capital funds, totaling approximately $3.75 billion in capital commitments.
Two South Park Street Suite 100 San Francisco, CA 94107
434 Broadway Sixth Floor New York, NY 10013
564 University Avenue Palo Alto, CA 94301
20 University Road Fourth Floor Cambridge, MA 02138
Adrian Abeijon
Investor
Mark Allen
CFO
Neeraj Arora
Managing Director, Investment Team
Juliet Bailin
Principal
Marc Bhargava
Managing Director
Chris Bischoff
Managing Director
Larry Bohn
Managing Director
Teresa Carlson
President, General Catalyst Institute
Kenneth Chenault
Chairman and Managing Director
Quentin Clark
Managing Director
Mark Crane
Partner
Christopher Davis
Partner
Kyle Doherty
Managing Director
Nick van Eck
Partner
Mina Hsiang
Associate
Nmachi Jidenma
Partner
Christopher Kauffman
Principal
Genevieve Kinney
Principal
Zak Kukoff
Principal
Paul Kwan
Managing Director
Viet Le
Partner
Roy Mabrey
Partner, Investment Team
Holly Maloney McConnell
Managing Director
Karanveer Mohan
Managing Director, Investment Team
Deep Nishar
Managing Director and Member of the Management Committee
Dipchand Nishar
Managing Director
Reva Nohria
Investor
Trevor Oelschig
Managing Director
Tyler Olkowski
Investor
Pranay Orugunta
Healthcare Investor
Mo Punjwani
Associate, Investments
Candace Richardson
Principal
Paul Sagan
Investor
Pranav Singhvi
Partner
Bill Skarinka
Associate
Alex Tran
Managing Director, Investments
Catherine Tu
Partner, Investment Team
Elena Viboch
Partner
Andrea Wang
Principal, Early Stage Investment
Nathaniel Levy-Westhead
Partner, Investment Team
Past deals in Medical
Stance Health
Pre Seed Round in 2025
Stance Health is a health technology company specializing in musculoskeletal (MSK) care. It develops a health and wellness platform that integrates medical science and technology to deliver evidence-based orthopedic rehabilitation. The company focuses on performance recovery and prevention, offering personalized programs for individuals with MSK conditions. Services include advanced diagnostic tools, tailored rehabilitation plans, and ongoing assessments, helping patients recover, prevent injuries, and improve their overall physical well-being.
Sohar Health
Seed Round in 2025
Sohar Health is a platform focused on enhancing the operations of behavioral health companies through a cloud-based eligibility verification and utilization reporting system. It provides an API-driven solution that facilitates eligibility verification and employs AI-powered medical coding to streamline manual workflows. The platform includes features designed to automate processes, manage eligibility files securely, and offer utilization analytics and reporting. This comprehensive approach enables digital health providers to scale their operations efficiently and increase revenue.
Maxion Therapeutics
Series A in 2025
Maxion Therapeutics specializes in developing innovative therapies through its drug discovery platform, which focuses on creating antibody-like therapeutics targeting ion channel and GPCR-driven diseases. The company utilizes unique ion channel-modulating mini-proteins, known as knottins, derived from venom and other sources, integrating them with antibody frameworks. This approach preserves the functional properties of knottins while enhancing the drug-like characteristics typical of antibodies. By doing so, Maxion Therapeutics aims to provide long-acting, safe, and effective treatments for conditions such as chronic pain, autoimmune disorders, and heart disease, addressing previously inaccessible therapeutic targets.
Manas AI
Seed Round in 2025
Manas AI uses proprietary AI, generative computational chemistry, and best-in-class biology to reduce the time and expense of traditional medicinal development while also revolutionizing cancer and rare illness treatments.
Neko Health
Series B in 2025
Neko Health is a Swedish health-tech company focused on enhancing healthcare through prevention and early detection of diseases. It has developed innovative medical scanning technology that enables comprehensive and non-invasive health data collection, making it accessible and affordable for the general public. By leveraging sensor technology and artificial intelligence, Neko Health aims to reduce the prevalence of common diseases and their associated healthcare costs. The company provides doctors and clinicians with tools for flexible and cost-effective examinations, ultimately aiming to improve the quality of healthcare and promote proactive health management.
OASYS NOW
Seed Round in 2024
OASYS NOW is a technology platform focused on improving the treatment journey for chronic patients by efficiently connecting them with relevant clinical trials tailored to their unique health data. The platform utilizes advanced algorithms to match patients with suitable global clinical trials, thereby increasing their opportunities for personalized treatment options. OASYS NOW emphasizes patient privacy through a privacy-by-design approach while harnessing extensive medical data to enhance health outcomes. Additionally, the company provides secure data-sharing solutions and ethical data processing systems aimed at organizations in the health and genomics sectors, ensuring a robust and secure infrastructure for sensitive health information.
Medeloop
Series A in 2024
Medeloop is a pioneering platform that enhances medical research through advanced artificial intelligence and a robust data linkage infrastructure. It integrates and analyzes vast amounts of health data, transforming it into a graph database that provides deeper insights and connectivity. This technology streamlines the clinical research process by offering research hypotheses for underexplored diseases, thereby enabling researchers to publish findings more efficiently. Additionally, Medeloop features a patient-facing application that empowers individuals to monitor their health information and actively contribute to significant medical research. By facilitating collaboration among patients, providers, and researchers, Medeloop aims to accelerate the discovery of biomarkers and potential drug targets, ultimately improving treatment development and saving lives.
Alpha9 Theranostics
Series C in 2024
Alpha9 Theranostics is a biopharma company that focuses on radiotherapeutics for the treatment of solid and hematologic malignancies. The company is creating a strong pipeline of radiopharmaceuticals to target solid and hematologic malignancies. Its systematic approach to radiotherapeutic design is fueled by a toolbox of technologies and chemistries, which offers broad potential for expansion into a multitude of oncology targets. Alpha9 Theranostics was founded in 2019 and is headquartered in Vancouver, Canada.
Primus
Seed Round in 2024
Primus helps elderly people slow the aging process by eliminating loneliness and achieving 'Zero Falls'. We ensure that we are proactive rather than reactive by conducting a series of examinations prior to onboarding elders so that they can be monitored by our in-house medical staff under a personalized care plan.
Astrix Health
Pre Seed Round in 2024
Astrix Health, based in San Francisco, New York, and London, specializes in AI-driven procurement solutions for healthcare providers. The company employs generative AI to analyze vast amounts of data, helping providers secure favorable terms on recurring medical supplies, equipment, and pharmaceutical orders. Astrix's team, comprising experts from Palantir, Oxford, Duke Health, and MedStar Health, aggregates and normalizes data from millions of sources to deliver actionable pricing insights. The company operates globally, backed by Y Combinator.
Maven Clinic
Series F in 2024
Maven Clinic is an on-demand digital care clinic focused on supporting mothers and families during conception, pregnancy, and the postpartum period. Founded in 2014 and headquartered in New York City, the clinic provides video appointments and private messaging with a network of women's and family health practitioners. Its comprehensive services cater to various needs, including IVF and egg-freezing tracks, pregnancy, postpartum, partner support, adoption, surrogacy, and loss. Additionally, Maven Clinic offers career coaching, support, and customized training for human resources managers. The company serves individuals, employers, and healthcare professionals, aiming to enhance family health and well-being through accessible digital care solutions.
Doccla
Series B in 2024
Doccla is a provider of virtual ward services that focuses on shifting patient care from hospitals to home settings. The company partners with care organizations to facilitate early patient discharge and reduce hospital readmissions through remote monitoring using advanced medical devices. By onboarding patients at home with the necessary monitoring equipment, Doccla employs a mobile team of healthcare professionals, including nurses and doctors, to oversee patient care. This approach not only ensures that patients receive timely and effective treatment but also aims to enhance care quality while lowering associated costs. Originally developed as part of a research initiative for the NHS, Doccla's innovative service has been successfully implemented in collaboration with Northampton General Hospital.
HarmonyCares
Venture Round in 2024
HarmonyCares specializes in delivering comprehensive medical care directly to clients in their homes. The company focuses on individuals with multiple chronic conditions, cognitive challenges, and psychosocial issues, offering a range of services that include primary and specialty care programs, home health services, hospice and palliative care, as well as diagnostic services such as radiology and laboratory testing. By providing high-quality, integrated care in a comfortable setting, HarmonyCares aims to meet the diverse health needs of patients, particularly the elderly, while also supplying durable medical equipment to enhance their home care experience. Rebranded from U.S. Medical Management in 2022, HarmonyCares emphasizes a physician-driven approach to ensure optimal health outcomes for its clients.
Better Health
Series A in 2024
Better Health is a support and supplies platform designed to improve the management of chronic conditions such as ostomy, chronic wounds, diabetes, chronic retention, and incontinence through peer-to-peer connections. The platform offers expert guidance to help patients select and use the appropriate medical supplies while providing education and support to enhance engagement and adherence to treatment. This approach is endorsed by healthcare payers and providers, leading to better health outcomes, reduced overutilization of services, and improved mental health for users. Better Health operates across 48 states and collaborates with major payers, including Medicare, Medicaid, and several private insurers. The platform boasts a high customer satisfaction rating of 98%, reflecting its effectiveness in modernizing the medical supplies industry and lowering healthcare costs for insurers and patients alike.
Hona AI
Seed Round in 2024
Hona AI is an AI data platform that collects and maintains healthcare history and records of patients.
Karius
Series C in 2024
Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.
Transcarent
Series D in 2024
Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.
Chamber Cardio
Seed Round in 2024
Chamber Cardio is a healthcare platform focused on enhancing cardiovascular health services by facilitating the transition of cardiologists to value-based care. The company provides a range of services, including panel management with real-time updates, financial metrics, and clinical data consolidated into a user-friendly dashboard. Additionally, it offers software support to manage complex patient cases and engages in value-based contracting. This comprehensive approach aims to improve treatment accessibility for patients and streamline operations within the healthcare sector.
Overjet
Series C in 2024
Overjet, Inc. is a leading developer of artificial intelligence software designed to analyze dental clinical data, enhancing the quality of patient care in dental practices. Founded by experts from MIT and Harvard University in 2018 and based in Allston, Massachusetts, Overjet offers clinical optimization software that assesses practice performance and identifies growth opportunities. Additionally, its utilization software automates the review of claims to pinpoint over- and under-utilization, thereby facilitating appropriate patient care at reduced costs. The company's FDA-cleared technology serves as an objective standard for oral health decisions, enabling dentists to accurately detect pathologies and effectively educate patients. Through its innovative AI solutions, Overjet aims to empower dental providers and payers to improve patient outcomes in the dental industry.
Fabric
Series A in 2024
Fabric is a health tech company that enables healthcare providers to deliver faster, higher quality, and more accessible care while reducing costs via consumer-grade patient experiences that automate workflows for staff.
Summa Health
Acquisition in 2024
Summa Health is a comprehensive healthcare provider that focuses on delivering integrated and coordinated care across a network of facilities. This network includes hospitals, community health centers, and a health plan, alongside a physician-hospital organization and a multi-specialty physician organization. Summa Health emphasizes personalized patient-centered care, particularly through its specialized Cancer Centers, which utilize advanced treatment technology and medical expertise to support whole-person healing. Additionally, the organization is involved in research and operates various foundations to enhance healthcare delivery and improve patient outcomes.
Harbor Health
Series A in 2024
Harbor Health is a multi-specialty clinic group based in Austin, Texas, founded in 2022. The organization focuses on delivering personalized, patient-centered healthcare by utilizing technology to enhance the patient experience. Harbor Health offers a collaborative approach to healthcare, working closely with individuals to understand their health goals and providing access to specialists when necessary. The clinic provides a variety of services, including primary care, chronic disease management, behavioral health, and overall wellness. Patients benefit from same-day and virtual appointment options, as well as conveniently located clinics, ensuring that healthcare is accessible and responsive to their needs.
Devoted
Series E in 2023
Devoted Health, established in 2017 and headquartered in Newton, Massachusetts, specializes in providing comprehensive healthcare solutions for Medicare beneficiaries in the United States. The company offers Medicare Advantage plans, along with personalized care through dedicated health guides, both in-person and virtually. Devoted Health aims to improve the health and well-being of older Americans by combining access to top local providers, virtual and in-home care through Devoted Medical, and advanced technology to deliver tailored healthcare experiences.
Layer Health
Seed Round in 2023
Layer Health is a technology company specializing in AI-driven healthcare information solutions. It develops an AI-powered platform designed to help healthcare providers extract valuable insights from patient data, enabling them to make informed decisions, enhance patient care, and improve overall efficiency. The platform focuses on processing unstructured data from clinical, administrative, and research sources, transforming it into actionable insights to support providers in their clinical and operational tasks.
Commure
Venture Round in 2023
Commure, Inc. is an innovative company that has developed an open platform aimed at healthcare software developers. Founded in 2017 and headquartered in San Francisco, California, with additional offices in Boston, Montreal, and Bogota, Commure provides a comprehensive developer platform that facilitates the creation and deployment of next-generation healthcare applications. This platform is built on the open HL7 FHIR standard, offering essential features such as an FHIR API server, security framework, event service bus, EHR integration, and more. By unifying disparate datasets and delivering meaningful insights, Commure enhances performance and fosters collaboration among doctors, nurses, and patients, ultimately empowering the healthcare ecosystem to improve care delivery. The company's commitment to interoperability and innovation positions it as a leader in the healthcare technology space.
Medeloop
Seed Round in 2023
Medeloop is a pioneering platform that enhances medical research through advanced artificial intelligence and a robust data linkage infrastructure. It integrates and analyzes vast amounts of health data, transforming it into a graph database that provides deeper insights and connectivity. This technology streamlines the clinical research process by offering research hypotheses for underexplored diseases, thereby enabling researchers to publish findings more efficiently. Additionally, Medeloop features a patient-facing application that empowers individuals to monitor their health information and actively contribute to significant medical research. By facilitating collaboration among patients, providers, and researchers, Medeloop aims to accelerate the discovery of biomarkers and potential drug targets, ultimately improving treatment development and saving lives.
Georgiamune
Series A in 2023
Georgiamune is an immunotherapy company dedicated to advancing oncology treatments. The firm specializes in next-generation immunotherapeutic and homeostatic therapies aimed at addressing cancer and autoimmune diseases. By focusing on innovative approaches, Georgiamune seeks to enhance patient recovery from cancer, contributing to significant breakthroughs in the field of immunotherapy.
Neko Health
Series A in 2023
Neko Health is a Swedish health-tech company focused on enhancing healthcare through prevention and early detection of diseases. It has developed innovative medical scanning technology that enables comprehensive and non-invasive health data collection, making it accessible and affordable for the general public. By leveraging sensor technology and artificial intelligence, Neko Health aims to reduce the prevalence of common diseases and their associated healthcare costs. The company provides doctors and clinicians with tools for flexible and cost-effective examinations, ultimately aiming to improve the quality of healthcare and promote proactive health management.
Berry Health
Pre Seed Round in 2023
Berry Health is a consumer health startup dedicated to improving lives by addressing under-served and stigmatized medical conditions. The company specializes in remote diagnosis and treatment for chronic health issues through online private medical consultations. Berry Health provides prescription medications and nationwide delivery, empowering patients to take control of their health. The services offered cover a wide range of conditions, including dermatology, mental health, sexual health, hair loss, and more, benefiting both men and women. By focusing on enhancing patient agency, Berry Health aims to promote better health outcomes, reduce inflammation and pain, optimize immunity, and improve brain health.
Memora Health
Venture Round in 2023
Memora Health Inc., founded in 2016 and based in San Francisco, California, develops an enterprise healthcare productivity platform aimed at automating outpatient communication and enhancing care delivery. The company partners with health systems, health plans, and digital health organizations to streamline clinical workflows, allowing clinicians to focus on their primary responsibilities while proactively engaging patients throughout their care journeys. Memora's platform digitizes high-touch processes, intelligently triaging patient-reported data to the relevant care team members and facilitating proactive, two-way communication between patients and providers. By transforming the way care is delivered, Memora Health seeks to make healthcare more actionable, accessible, and continuous.
Maribel Health
Series A in 2023
Maribel Health focuses on developing and operating advanced clinical care models that deliver healthcare services in home and community settings. The company aims to enhance the overall capacity of health systems and improve patient access by offering innovative home-based care solutions. In addition to its care models, Maribel Health provides assessment and planning services for home and community-based care, addressing the specific needs of local markets and healthcare organizations. Through these initiatives, the company seeks to facilitate better healthcare delivery and support the strategic goals of its partners.
Faro Health
Series A in 2023
Faro Health is a developer of a cloud-based medical platform aimed at addressing the complexities of clinical trials. The platform standardizes, automates, and streamlines various challenges associated with clinical studies. By utilizing an integrated clinical development environment, Faro Health simplifies the design and authoring of complex clinical protocols. This system leverages advanced digital protocols to provide intuitive insights during the authoring process, allowing clinical researchers to focus on critical decisions that enhance clinical value while minimizing administrative burdens.
Paradigm
Series A in 2023
Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.
Vial
Series B in 2022
Vial is a biotech company that focuses on enhancing the efficiency and affordability of clinical trials. By partnering with clinics, Vial transforms them into clinical trial research sites equipped with the necessary technology and infrastructure. The company's platform manages various aspects of clinical trials, including administrative tasks, data entry, patient scheduling and recruitment, invoicing, and compliance. This comprehensive approach allows biotechnology companies to navigate different phases of drug development more effectively while also providing partner clinics with opportunities to increase their revenue. Vial's emphasis on automation and advanced technologies positions it as a key player in the evolution of clinical trial processes.
Vial
Series A in 2022
Vial is a biotech company that focuses on enhancing the efficiency and affordability of clinical trials. By partnering with clinics, Vial transforms them into clinical trial research sites equipped with the necessary technology and infrastructure. The company's platform manages various aspects of clinical trials, including administrative tasks, data entry, patient scheduling and recruitment, invoicing, and compliance. This comprehensive approach allows biotechnology companies to navigate different phases of drug development more effectively while also providing partner clinics with opportunities to increase their revenue. Vial's emphasis on automation and advanced technologies positions it as a key player in the evolution of clinical trial processes.
Maven Clinic
Series E in 2022
Maven Clinic is an on-demand digital care clinic focused on supporting mothers and families during conception, pregnancy, and the postpartum period. Founded in 2014 and headquartered in New York City, the clinic provides video appointments and private messaging with a network of women's and family health practitioners. Its comprehensive services cater to various needs, including IVF and egg-freezing tracks, pregnancy, postpartum, partner support, adoption, surrogacy, and loss. Additionally, Maven Clinic offers career coaching, support, and customized training for human resources managers. The company serves individuals, employers, and healthcare professionals, aiming to enhance family health and well-being through accessible digital care solutions.
Doccla
Series A in 2022
Doccla is a provider of virtual ward services that focuses on shifting patient care from hospitals to home settings. The company partners with care organizations to facilitate early patient discharge and reduce hospital readmissions through remote monitoring using advanced medical devices. By onboarding patients at home with the necessary monitoring equipment, Doccla employs a mobile team of healthcare professionals, including nurses and doctors, to oversee patient care. This approach not only ensures that patients receive timely and effective treatment but also aims to enhance care quality while lowering associated costs. Originally developed as part of a research initiative for the NHS, Doccla's innovative service has been successfully implemented in collaboration with Northampton General Hospital.
Redesign Health
Series C in 2022
Redesign Health is a company founded in 2018 that focuses on driving innovation in the healthcare sector. It develops technologies, tools, and insights designed to lower barriers to change within the industry. Redesign Health collaborates with exceptional founders to create and support over two dozen companies that have collectively impacted more than ten million lives across various healthcare domains, including cancer care, teleradiology, COVID-19 testing, and metabolic health. By fostering the growth of diverse healthcare solutions, Redesign Health aims to enhance the overall efficiency and effectiveness of healthcare delivery.
Plume Clinic
Series B in 2022
Plume is a health tech company for the transgender community. The company focuses on radically increasing access to care, medication, and products for the trans community, supporting a bold, authentic and healthy lifestyle. Its vision is to make gender-affirming care available to anyone until it transforms healthcare for every trans life.
Homeward
Series B in 2022
Homeward is focused on transforming healthcare services for the 60 million Americans residing in rural areas. The company utilizes multidisciplinary care teams that operate both virtually and through mobile care units, ensuring comprehensive and accessible healthcare. Homeward employs in-home remote monitoring technology to enhance patient connections to high-quality and affordable care. By partnering with Medicare Advantage plans, the organization assumes full financial risk for its members, aiming to improve health outcomes while reducing costs. Through these initiatives, Homeward seeks to provide effective support to Medicare-eligible beneficiaries in underserved communities.
Examedi
Series A in 2022
Examedi is a healthcare startup that facilitates at-home medical services by connecting patients with independent nurses and lab technicians. Through its telemedicine platform, Examedi allows patients to book diagnostic tests and examinations, including blood tests, pregnancy tests, general checkups, and COVID tests. This service prioritizes accessibility and affordability, ensuring that patients can receive necessary medical care in the comfort of their homes. By coordinating the schedules of healthcare providers with patient needs, Examedi aims to enhance the convenience and efficiency of healthcare delivery.
Osmind
Series B in 2022
Osmind Inc., established in 2020 and headquartered in San Jose, California, specializes in designing and developing healthcare software tailored for mental health providers and their patients. The company, led by a team of scientists, technologists, and psychiatrists, aims to advance evidence-based medicine for individuals with moderate to severe mental health conditions. Osmind's core product is a mental health operating platform, which includes an electronic health record system designed for interventional treatment workflows. This platform offers tools such as journaling and assistance with health plan reimbursement, enabling clinicians to explore novel therapeutic approaches and precision psychiatry, ultimately enhancing patient care.
Loop
Series B in 2022
Loop Health is a healthcare provider based in Pune, India, founded in 2018. The company offers a range of services including acute and urgent care, chronic condition management, women's health, health coaching, and preventive care. Loop Health aims to simplify the healthcare experience by connecting patients with family physicians, specialists, and hospitals, facilitating access to major medical treatments. Their team of Loop Coordinators assists patients in finding appropriate doctors, comparing treatment costs, obtaining second opinions, and managing admission procedures, thereby alleviating the stress associated with healthcare decisions. Additionally, Loop Health features a virtual medical practice that supports employees and their families, allowing them to consult with healthcare experts and medical advisors without delay, ultimately promoting better health management and cost-effectiveness.
Alinea Health
Venture Round in 2022
Alinea Health is a health-tech startup that provides solutions for corporate health. It utilizes large amounts of data and proprietary algorithms to assist the client company's beneficiaries in navigating their health plans, providing personalized and unbiased guidance, recommendations from the most effective doctors in the accredited network, and conveniences such as scheduling consultations and exams. In addition to continuous monitoring, its doctors use the Lifestyle Medicine methodology to promote a healthy lifestyle and lower the risk of developing chronic diseases.
Homeward
Series A in 2022
Homeward is focused on transforming healthcare services for the 60 million Americans residing in rural areas. The company utilizes multidisciplinary care teams that operate both virtually and through mobile care units, ensuring comprehensive and accessible healthcare. Homeward employs in-home remote monitoring technology to enhance patient connections to high-quality and affordable care. By partnering with Medicare Advantage plans, the organization assumes full financial risk for its members, aiming to improve health outcomes while reducing costs. Through these initiatives, Homeward seeks to provide effective support to Medicare-eligible beneficiaries in underserved communities.
Story Health
Series A in 2022
Story Health Corporation, founded in 2020 and based in Saratoga, California, develops advanced virtualized clinical care software tools aimed at aiding healthcare specialists, particularly neurologists and primary care physicians. The company offers a comprehensive healthcare technology platform that includes virtual patient programs, therapy management, and analytics designed to bridge the gap between clinical evidence and patient experiences. By utilizing data from high-frequency sources, Story Health empowers clinicians to better understand medical situations and make informed decisions regarding the physiological impacts of diseases and therapies. Through its innovative approach, Story Health enhances the ability of specialists to deliver effective patient care.
Ro
Venture Round in 2022
Ro is a telehealth company established in New York City in 2017, specializing in digital health clinics that cater to both men's and women's health, as well as smoking cessation. It offers a patient-centric healthcare system that integrates primary care services, diagnostics, and pharmacy solutions. The platform facilitates direct communication between patients and physicians, providing an end-to-end healthcare experience that encompasses diagnosis, medication delivery, and ongoing care management. Ro's services include personalized treatment options for issues such as erectile dysfunction and smoking cessation, all designed to enhance accessibility and affordability without relying on insurance. The company operates a nationwide provider network, incorporates an in-home care API, and utilizes proprietary pharmacy distribution centers to streamline healthcare services for its users.
Dewpoint Therapeutics
Series C in 2022
Dewpoint Therapeutics is a Boston-based biotech company focused on the research and development of treatments targeting biomolecular condensates to address various diseases, including cancer, neurodegenerative disorders, and immunological conditions. Founded in 2018, the company employs an innovative drug platform that utilizes machine-learning-based image analysis for visualizing condensates. This technology supports an engine of engineered cell lines designed to track and mitigate harmful protein sequestration. By leveraging its proprietary platform, Dewpoint seeks to facilitate drug discovery across a wide range of medical indications and collaborates with leading academic and pharmaceutical partners to enhance the accessibility of new therapies for unmet healthcare needs.
Jasper Health
Series A in 2022
Jasper Health is a digital platform based in Boise, Idaho, that provides psychosocial support to cancer patients through telemedicine and a personalized planning application known as the Cancer Care Companion. Founded in 2018, the platform enables users to connect with caregivers, healthcare providers, and support teams from employers and health plans. Its smart application features tools for organizing appointments, tracking symptoms, side effects, and moods, as well as curating necessary products. This comprehensive approach helps patients stay organized while activating support from family and friends, enhancing their overall care experience. Jasper Health serves tens of thousands of members, focusing on personalized support tailored to the unique challenges faced by individuals living with cancer.
Transcarent
Series C in 2022
Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.
Maze Therapeutics
Venture Round in 2022
Maze Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative medicines that leverage the effects of rare genetic variants to address unmet medical needs. Founded in 2017 and originally known as Modulus Therapeutics, the company utilizes its proprietary Compass platform to identify genetic variants linked to diseases and map them to the biological pathways that drive these conditions in specific patient populations. By integrating large-scale human genetics data and functional genomics with various drug discovery methods, Maze Therapeutics aims to reveal modifier genes that offer protective benefits. This approach enhances the understanding of target biology and informs the development of novel therapies, ultimately enabling pharmaceutical companies to create effective treatments.
Overjet
Series B in 2021
Overjet, Inc. is a leading developer of artificial intelligence software designed to analyze dental clinical data, enhancing the quality of patient care in dental practices. Founded by experts from MIT and Harvard University in 2018 and based in Allston, Massachusetts, Overjet offers clinical optimization software that assesses practice performance and identifies growth opportunities. Additionally, its utilization software automates the review of claims to pinpoint over- and under-utilization, thereby facilitating appropriate patient care at reduced costs. The company's FDA-cleared technology serves as an objective standard for oral health decisions, enabling dentists to accurately detect pathologies and effectively educate patients. Through its innovative AI solutions, Overjet aims to empower dental providers and payers to improve patient outcomes in the dental industry.
Ophelia
Series B in 2021
Ophelia Health, established in 2019 and headquartered in New York, specializes in medication-assisted treatment for opioid dependency. The company facilitates telemedicine consultations between patients and doctors, and provides necessary medications. Ophelia Health differentiates itself by combining medical expertise with a client-centered approach, prioritizing privacy and empowering individuals to make their own treatment decisions.
Cadence Solutions
Series B in 2021
Cadence is a pioneering health technology company helping the nation’s largest health systems deliver world-class care outside of the four walls of the hospital.
Sword Health
Series D in 2021
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.
Variant Bio
Series B in 2021
Variant Bio Inc. is a biotechnology company based in Seattle, Washington, that focuses on developing therapeutics through the study of human genetic diversity. Founded in 2018, the company identifies individuals and populations that exhibit extreme traits of medical significance, utilizing advanced sequencing technologies and analytic methods to uncover the genes and pathways associated with these traits. By leveraging insights from genetic research, Variant Bio aims to discover new therapeutic targets for conditions such as neurodegenerative, autoimmune, and cardiometabolic diseases. The company's innovative approach combines statistical genetics and machine learning, enhancing the potential for genomic drug discovery to address unmet medical needs.
Beacon Biosignals
Series A in 2021
Beacon Biosignals is a company focused on enhancing human health through the application of artificial intelligence in the analysis of brain activity. It has developed a platform that provides rapid and accurate electroencephalogram (EEG) reports, streamlining the diagnostic process by eliminating the need for adjudication and utilizing improved criteria for inclusion and exclusion. The platform captures real-time brain activity, supporting healthcare professionals in the study of neurological and psychiatric disorders. By enabling more precise quantification of treatment plans and helping identify optimal patient populations, Beacon Biosignals aims to facilitate targeted interventions and advance the field of brain analytics.
Zerigo Health
Series B in 2021
Zerigo Health, formerly known as Clarify Medical, Inc., specializes in home therapy solutions for chronic skin conditions such as psoriasis, eczema, and vitiligo. The company offers innovative products like the Clarify mobile ultra violet B treatment system and the Home Light Therapy System, both designed to facilitate phototherapy in a home setting. Zerigo Health aims to enhance the ease and effectiveness of UVB therapy through a connected system that allows patients to manage their treatment via a smartphone app. This app enables users to control dosing, frequency, and duration of therapy, ensuring adherence to guidelines set by dermatology experts. By allowing patients to administer their treatments with clinical precision, Zerigo Health improves the overall patient experience, while also monitoring compliance and progress, ultimately empowering individuals to manage their chronic skin conditions more effectively from the comfort of their homes.
Better Health
Series A in 2021
Better Health is a support and supplies platform designed to improve the management of chronic conditions such as ostomy, chronic wounds, diabetes, chronic retention, and incontinence through peer-to-peer connections. The platform offers expert guidance to help patients select and use the appropriate medical supplies while providing education and support to enhance engagement and adherence to treatment. This approach is endorsed by healthcare payers and providers, leading to better health outcomes, reduced overutilization of services, and improved mental health for users. Better Health operates across 48 states and collaborates with major payers, including Medicare, Medicaid, and several private insurers. The platform boasts a high customer satisfaction rating of 98%, reflecting its effectiveness in modernizing the medical supplies industry and lowering healthcare costs for insurers and patients alike.
Devoted
Series D in 2021
Devoted Health, established in 2017 and headquartered in Newton, Massachusetts, specializes in providing comprehensive healthcare solutions for Medicare beneficiaries in the United States. The company offers Medicare Advantage plans, along with personalized care through dedicated health guides, both in-person and virtually. Devoted Health aims to improve the health and well-being of older Americans by combining access to top local providers, virtual and in-home care through Devoted Medical, and advanced technology to deliver tailored healthcare experiences.
Loop
Series A in 2021
Loop Health is a healthcare provider based in Pune, India, founded in 2018. The company offers a range of services including acute and urgent care, chronic condition management, women's health, health coaching, and preventive care. Loop Health aims to simplify the healthcare experience by connecting patients with family physicians, specialists, and hospitals, facilitating access to major medical treatments. Their team of Loop Coordinators assists patients in finding appropriate doctors, comparing treatment costs, obtaining second opinions, and managing admission procedures, thereby alleviating the stress associated with healthcare decisions. Additionally, Loop Health features a virtual medical practice that supports employees and their families, allowing them to consult with healthcare experts and medical advisors without delay, ultimately promoting better health management and cost-effectiveness.
Overjet
Series A in 2021
Overjet, Inc. is a leading developer of artificial intelligence software designed to analyze dental clinical data, enhancing the quality of patient care in dental practices. Founded by experts from MIT and Harvard University in 2018 and based in Allston, Massachusetts, Overjet offers clinical optimization software that assesses practice performance and identifies growth opportunities. Additionally, its utilization software automates the review of claims to pinpoint over- and under-utilization, thereby facilitating appropriate patient care at reduced costs. The company's FDA-cleared technology serves as an objective standard for oral health decisions, enabling dentists to accurately detect pathologies and effectively educate patients. Through its innovative AI solutions, Overjet aims to empower dental providers and payers to improve patient outcomes in the dental industry.
Cadence Solutions
Series A in 2021
Cadence is a pioneering health technology company helping the nation’s largest health systems deliver world-class care outside of the four walls of the hospital.
Aidoc
Series C in 2021
Aidoc is a company based in Tel Aviv, Israel, specializing in artificial intelligence solutions for healthcare, particularly in the field of medical imaging. Founded in 2016, Aidoc has developed a platform that enhances the efficiency of radiologists by analyzing medical scans immediately after they are performed. Its AI-driven technology identifies critical anomalies and suggests the prioritization of time-sensitive pathologies, enabling healthcare professionals to respond swiftly and effectively. This approach helps to reduce turnaround times, decrease hospital stays, and ultimately improve patient outcomes. Aidoc's decision support software leverages deep learning algorithms to assist radiologists in making accurate diagnoses, thereby transforming the medical imaging process.
Osmind
Series A in 2021
Osmind Inc., established in 2020 and headquartered in San Jose, California, specializes in designing and developing healthcare software tailored for mental health providers and their patients. The company, led by a team of scientists, technologists, and psychiatrists, aims to advance evidence-based medicine for individuals with moderate to severe mental health conditions. Osmind's core product is a mental health operating platform, which includes an electronic health record system designed for interventional treatment workflows. This platform offers tools such as journaling and assistance with health plan reimbursement, enabling clinicians to explore novel therapeutic approaches and precision psychiatry, ultimately enhancing patient care.
Sword Health
Series C in 2021
Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.
Transcarent
Series B in 2021
Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.
PathAI
Series C in 2021
PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.
Ophelia
Series A in 2021
Ophelia Health, established in 2019 and headquartered in New York, specializes in medication-assisted treatment for opioid dependency. The company facilitates telemedicine consultations between patients and doctors, and provides necessary medications. Ophelia Health differentiates itself by combining medical expertise with a client-centered approach, prioritizing privacy and empowering individuals to make their own treatment decisions.
Oath Care
Seed Round in 2021
Oath Care is developing an innovative model of group-based, continuous healthcare aimed at enhancing health outcomes for children. The company operates an online platform that connects medical providers with families, fostering intimate connections and shared parental experiences. Through this platform, users can access specialist support and guidance via group chats and one-on-one video calls. This approach allows patients to receive tailored medical and emotional support, addressing their individual needs effectively.
Ro
Series D in 2021
Ro is a telehealth company established in New York City in 2017, specializing in digital health clinics that cater to both men's and women's health, as well as smoking cessation. It offers a patient-centric healthcare system that integrates primary care services, diagnostics, and pharmacy solutions. The platform facilitates direct communication between patients and physicians, providing an end-to-end healthcare experience that encompasses diagnosis, medication delivery, and ongoing care management. Ro's services include personalized treatment options for issues such as erectile dysfunction and smoking cessation, all designed to enhance accessibility and affordability without relying on insurance. The company operates a nationwide provider network, incorporates an in-home care API, and utilizes proprietary pharmacy distribution centers to streamline healthcare services for its users.
Ossium Health
Series B in 2021
Ossium Health, Inc. is engaged in the development and manufacturing of cell therapy products aimed at treating leukemia, other blood cancers, and tissue damage, as well as addressing radiation poisoning. The company offers a range of innovative therapies, including HPC, Marrow, which features HLA-matched bone marrow stem cells for hematopoietic reconstitution in blood cancer patients; Chimera, which enhances organ transplantation; and Chymalis, composed of mesenchymal stem cells that promote the healing of damaged bone and muscle tissue. Additionally, Ossium provides bone marrow cells for research purposes in oncology and immunology. Founded in 2016 and headquartered in San Francisco, California, Ossium Health focuses on improving health outcomes and longevity through advanced bioengineering techniques.
Plume Clinic
Series A in 2021
Plume is a health tech company for the transgender community. The company focuses on radically increasing access to care, medication, and products for the trans community, supporting a bold, authentic and healthy lifestyle. Its vision is to make gender-affirming care available to anyone until it transforms healthcare for every trans life.
Elephant Healthcare
Series A in 2021
Elephant Healthcare Limited, founded in 2018 and based in London, develops a digital health system aimed at revolutionizing global healthcare. The company constructs a global digital health network that links various components of the healthcare ecosystem. Founded by medical professionals, Elephant leverages technological innovations to tackle significant challenges in healthcare, focusing on cost reduction and improving patient outcomes. Its software platform digitizes medical clinics, fostering connectivity and providing tools to enhance primary care. Additionally, the platform utilizes blockchain and decentralized infrastructure to integrate existing services and facilitate the development of new health applications, particularly benefiting hospitals serving low-income populations.
Curai Health
Series B in 2020
Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company leverages artificial intelligence to provide chat-based primary care services, aiming to make high-quality and affordable healthcare accessible to everyone, anytime. Curai Health's platform integrates clinicians with advanced AI and machine learning tools to create a learning healthcare system that enhances the efficiency and cost-effectiveness of medical care. By facilitating better communication between patients and healthcare professionals, the platform aids in accurate diagnosis and treatment. Curai Health offers its services directly to consumers and through partnerships with enterprises.
Story Health
Seed Round in 2020
Story Health Corporation, founded in 2020 and based in Saratoga, California, develops advanced virtualized clinical care software tools aimed at aiding healthcare specialists, particularly neurologists and primary care physicians. The company offers a comprehensive healthcare technology platform that includes virtual patient programs, therapy management, and analytics designed to bridge the gap between clinical evidence and patient experiences. By utilizing data from high-frequency sources, Story Health empowers clinicians to better understand medical situations and make informed decisions regarding the physiological impacts of diseases and therapies. Through its innovative approach, Story Health enhances the ability of specialists to deliver effective patient care.
Olive
Venture Round in 2020
Olive deploys the AI workforce built specifically for healthcare, delivering hospitals and health systems increased revenue, reduced costs, and increased capacity. Olive automates repetitive, high-volume tasks and workflows, monitoring their performance, identifying improvements, and finding opportunities for new work. Olive gives power back to providers through her ever-growing, unparalleled intelligence made up of shared memories, collective wisdom, and global awareness, learning like a network so hospitals never have to solve the same problem twice. Olive was founded in 2012 and is headquartered in Columbus, Ohio.
Transcarent
Series A in 2020
Transcarent is a consumer-directed health and care platform designed for employees of self-insured employers and their families. The company utilizes a blend of software, technology, and data science to provide consumers with unbiased information and trusted guidance. By connecting users to a network of high-value healthcare providers and services, Transcarent aims to empower individuals to make informed choices and achieve better health outcomes while navigating the complexities of the healthcare system. This approach fosters transparency and cost-effective decision-making, addressing a wide range of healthcare challenges faced by consumers today.
Osmind
Seed Round in 2020
Osmind Inc., established in 2020 and headquartered in San Jose, California, specializes in designing and developing healthcare software tailored for mental health providers and their patients. The company, led by a team of scientists, technologists, and psychiatrists, aims to advance evidence-based medicine for individuals with moderate to severe mental health conditions. Osmind's core product is a mental health operating platform, which includes an electronic health record system designed for interventional treatment workflows. This platform offers tools such as journaling and assistance with health plan reimbursement, enabling clinicians to explore novel therapeutic approaches and precision psychiatry, ultimately enhancing patient care.
Olive
Series F in 2020
Olive deploys the AI workforce built specifically for healthcare, delivering hospitals and health systems increased revenue, reduced costs, and increased capacity. Olive automates repetitive, high-volume tasks and workflows, monitoring their performance, identifying improvements, and finding opportunities for new work. Olive gives power back to providers through her ever-growing, unparalleled intelligence made up of shared memories, collective wisdom, and global awareness, learning like a network so hospitals never have to solve the same problem twice. Olive was founded in 2012 and is headquartered in Columbus, Ohio.
Ro
Series C in 2020
Ro is a telehealth company established in New York City in 2017, specializing in digital health clinics that cater to both men's and women's health, as well as smoking cessation. It offers a patient-centric healthcare system that integrates primary care services, diagnostics, and pharmacy solutions. The platform facilitates direct communication between patients and physicians, providing an end-to-end healthcare experience that encompasses diagnosis, medication delivery, and ongoing care management. Ro's services include personalized treatment options for issues such as erectile dysfunction and smoking cessation, all designed to enhance accessibility and affordability without relying on insurance. The company operates a nationwide provider network, incorporates an in-home care API, and utilizes proprietary pharmacy distribution centers to streamline healthcare services for its users.
Ophelia
Seed Round in 2020
Ophelia Health, established in 2019 and headquartered in New York, specializes in medication-assisted treatment for opioid dependency. The company facilitates telemedicine consultations between patients and doctors, and provides necessary medications. Ophelia Health differentiates itself by combining medical expertise with a client-centered approach, prioritizing privacy and empowering individuals to make their own treatment decisions.
Olive
Series E in 2020
Olive deploys the AI workforce built specifically for healthcare, delivering hospitals and health systems increased revenue, reduced costs, and increased capacity. Olive automates repetitive, high-volume tasks and workflows, monitoring their performance, identifying improvements, and finding opportunities for new work. Olive gives power back to providers through her ever-growing, unparalleled intelligence made up of shared memories, collective wisdom, and global awareness, learning like a network so hospitals never have to solve the same problem twice. Olive was founded in 2012 and is headquartered in Columbus, Ohio.
Karius
Series B in 2020
Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.
PathAI
Series B in 2019
PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.
Curai Health
Series A in 2018
Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company leverages artificial intelligence to provide chat-based primary care services, aiming to make high-quality and affordable healthcare accessible to everyone, anytime. Curai Health's platform integrates clinicians with advanced AI and machine learning tools to create a learning healthcare system that enhances the efficiency and cost-effectiveness of medical care. By facilitating better communication between patients and healthcare professionals, the platform aids in accurate diagnosis and treatment. Curai Health offers its services directly to consumers and through partnerships with enterprises.
Ro
Seed Round in 2017
Ro is a telehealth company established in New York City in 2017, specializing in digital health clinics that cater to both men's and women's health, as well as smoking cessation. It offers a patient-centric healthcare system that integrates primary care services, diagnostics, and pharmacy solutions. The platform facilitates direct communication between patients and physicians, providing an end-to-end healthcare experience that encompasses diagnosis, medication delivery, and ongoing care management. Ro's services include personalized treatment options for issues such as erectile dysfunction and smoking cessation, all designed to enhance accessibility and affordability without relying on insurance. The company operates a nationwide provider network, incorporates an in-home care API, and utilizes proprietary pharmacy distribution centers to streamline healthcare services for its users.
PathAI
Series A in 2017
PathAI, Inc. is a technology company that specializes in developing artificial intelligence solutions for pathology laboratories. Founded in 2016 and headquartered in Boston, Massachusetts, with an additional office in Austin, Texas, PathAI focuses on enhancing the accuracy and efficiency of cancer diagnosis and treatment. The company's platform employs machine and deep learning techniques to analyze large datasets, assisting pathologists in making rapid and precise diagnoses for patients. By addressing complex challenges in pathology, PathAI aims to facilitate personalized medicine and improve patient outcomes by identifying individuals who may benefit from innovative therapies.
Commure
Seed Round in 2017
Commure, Inc. is an innovative company that has developed an open platform aimed at healthcare software developers. Founded in 2017 and headquartered in San Francisco, California, with additional offices in Boston, Montreal, and Bogota, Commure provides a comprehensive developer platform that facilitates the creation and deployment of next-generation healthcare applications. This platform is built on the open HL7 FHIR standard, offering essential features such as an FHIR API server, security framework, event service bus, EHR integration, and more. By unifying disparate datasets and delivering meaningful insights, Commure enhances performance and fosters collaboration among doctors, nurses, and patients, ultimately empowering the healthcare ecosystem to improve care delivery. The company's commitment to interoperability and innovation positions it as a leader in the healthcare technology space.
PatientBank
Seed Round in 2016
PatientBank offers an online platform that facilitates the requesting, storage, and sharing of medical records. This service enables patients to gather their medical information from various healthcare providers, including doctors and hospitals, and share it with family members or other care providers as needed. By streamlining the process of accessing and managing medical records, PatientBank aims to enhance the communication between patients and healthcare professionals, ultimately supporting better health management and checkups.
TearScience
Series D in 2016
TearScience, Inc. is a medical device company based in Morrisville, North Carolina, focused on the identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD), which is the primary cause of evaporative dry eye affecting over 100 million people globally. The company has developed innovative devices such as the LipiFlow Activator, which delivers automated therapeutic energies to meibomian glands while safeguarding the eye's delicate structures, and LipiScan, an imaging system that allows eye care professionals to assess gland health. MGD is often under-recognized and contributes significantly to dry eye symptoms such as irritation, dryness, and visual disturbances. By providing a comprehensive in-office system, TearScience enables eye care professionals to effectively address the root causes of evaporative dry eye, ultimately improving patient outcomes. The company, originally known as Kolis Scientific, Inc., was rebranded in 2005 and is now a subsidiary of Johnson & Johnson Surgical Vision, Inc.
Corvia
Series D in 2014
Corvia Medical, Inc., established in 2009 and based in Andover, Massachusetts, is a medical device company specializing in structural heart devices for heart failure treatment. Its primary product is the InterAtrial Shunt Device (IASD), a transcatheter device designed to alleviate symptoms and slow the progression of diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF). The IASD system reduces elevated left atrial pressure, the primary cause of DHF symptoms, by creating a small opening between the left and right atria, enabling patients to lead healthier lives with reduced heart failure risk.
Corvia
Series C in 2013
Corvia Medical, Inc., established in 2009 and based in Andover, Massachusetts, is a medical device company specializing in structural heart devices for heart failure treatment. Its primary product is the InterAtrial Shunt Device (IASD), a transcatheter device designed to alleviate symptoms and slow the progression of diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF). The IASD system reduces elevated left atrial pressure, the primary cause of DHF symptoms, by creating a small opening between the left and right atria, enabling patients to lead healthier lives with reduced heart failure risk.
SynapDx
Series B in 2012
SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.
Aidin
Venture Round in 2012
Aidin is a healthcare technology company focused on enhancing the discharge planning process for hospitals and social workers. Its platform streamlines the workflow for discharge planning professionals by automating the generation of provider listings, thereby minimizing administrative tasks and allowing social workers to concentrate more on patient care. Aidin provides patients with access to quality ratings and reviews of available post-acute care providers, facilitating informed decision-making. The platform also tracks patient experiences and outcomes, equipping case managers with valuable insights to identify the most effective providers for specific health conditions. By connecting patients with the right post-hospital care options, Aidin aims to reduce readmissions and improve overall patient satisfaction.
Humedica
Venture Round in 2012
Humedica is a clinical intelligence company that specializes in health analytics, providing tools for hospitals, physicians, and life sciences organizations. The company's primary offering, Humedica MinedShare, is a platform designed to transform unconnected data from various sources into actionable insights, enabling clients to make better-informed decisions. By facilitating clinical, operational, and financial benchmarking across the continuum of care, Humedica supports healthcare providers in enhancing the quality and efficiency of their services.
OvaScience
Series B in 2012
OvaScience, Inc. was a fertility company focused on developing innovative treatments for women facing infertility challenges. The company was founded in 2011 and was headquartered in Waltham, Massachusetts. OvaScience specialized in proprietary technology derived from the discovery of egg precursor (EggPC) cells, which allowed for the enhancement of egg quality and improved outcomes in in vitro fertilization (IVF). Their treatment options included OvaPrime, which aimed to restore a woman's egg production using her own EggPC cells, OvaTure, designed to mature these cells into fertilizable eggs outside the body, and AUGMENT, which utilized mitochondria from EggPC cells to enhance fertilization and pregnancy rates. The company also explored OvaXon for preventing inherited diseases. OvaScience was co-founded by a team of experts from Harvard Medical School and was backed by prominent life science investors. In December 2018, OvaScience was acquired by Millendo Therapeutics in a reverse merger.
Humedica
Venture Round in 2011
Humedica is a clinical intelligence company that specializes in health analytics, providing tools for hospitals, physicians, and life sciences organizations. The company's primary offering, Humedica MinedShare, is a platform designed to transform unconnected data from various sources into actionable insights, enabling clients to make better-informed decisions. By facilitating clinical, operational, and financial benchmarking across the continuum of care, Humedica supports healthcare providers in enhancing the quality and efficiency of their services.
SynapDx
Series A in 2010
SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.
TearScience
Series C in 2010
TearScience, Inc. is a medical device company based in Morrisville, North Carolina, focused on the identification, diagnosis, and treatment of Meibomian Gland Dysfunction (MGD), which is the primary cause of evaporative dry eye affecting over 100 million people globally. The company has developed innovative devices such as the LipiFlow Activator, which delivers automated therapeutic energies to meibomian glands while safeguarding the eye's delicate structures, and LipiScan, an imaging system that allows eye care professionals to assess gland health. MGD is often under-recognized and contributes significantly to dry eye symptoms such as irritation, dryness, and visual disturbances. By providing a comprehensive in-office system, TearScience enables eye care professionals to effectively address the root causes of evaporative dry eye, ultimately improving patient outcomes. The company, originally known as Kolis Scientific, Inc., was rebranded in 2005 and is now a subsidiary of Johnson & Johnson Surgical Vision, Inc.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.